Takeda announced on 14 July that its investigational oral OX2R agonist, oveporexton (TAK-861), met all primary and secondary endpoints in two Phase III trials for narcolepsy type 1 (NT1). The studies demonstrated statistically significant improvements in wakefulness, daytime sleepiness, cataplexy, attention, and quality of life, with symptom severity approaching normal ranges. Oveporexton's safety profile was consistent with prior studies, with no treatment-related serious adverse events reported. Takeda plans to submit regulatory filings globally in fiscal year 2025.

NT1 is a rare neurological disorder caused by loss of orexin-producing neurons, leading to debilitating symptoms. Current treatments only address symptoms, whereas oveporexton targets the underlying orexin deficiency. The FirstLight and RadiantLight trials enrolled 273 participants across 19 countries. Over 95% of participants opted into the long-term extension study. Takeda's CEO highlighted the drug's potential to transform NT1 treatment, marking a milestone in the company's neuroscience pipeline.

According to PharmCube's NextBiopharm® database, there are over 30 companies actively developing OX2R-targeted drugs, including some already on the market. Click here to request a free trial for NextBiopharm®.